Trazodone is generally well tolerated in patients with MDD and, compared to SSRIs and SNRIs it has a low risk for anxiety, insomnia, and sexual dysfunction, due to its simultaneous inhibition of 5-HT2A and 5-HT2C receptors, and serotonin transporters, along with its anti-alpha adrenergic and anti-histaminergic properties [11, 30]. This evidence concerns the gene HTR2A and major depressive disorder.